Skip to main content
. 2022 Dec 24;2022:8435581. doi: 10.1155/2022/8435581

Table 3.

Patients with suspected NAFLD.

Characteristics Total suspected NAFLD n (%) (N = 1046)
Age, years
 9–12 189 (18.1)
 13–18 857 (81.9)

Sex, % male 542 (51.8)

Location
 Rural 246 (24.0)
 Urban 781 (76.0)
 Missing 19

BMI, percentile
 ≥85th (underweight to normal) 7 (0.67)
 86th–94th (overweight) 4 (0.38)
 ≥95th–<99th (obese) 667 (63.8)
 ≥99th (severe obesity) 363 (34.7)
 Missing 5

ALT (n = 1021)
 Median ALT 31 (18)
 ALT >40 335 (32.3)
 ALT >80 82 (7.8)

Health conditions
 Diabetes 59 (5.64)
 Hypertension 95 (9.1)
 Dyslipidemia 179 (17.1)
 ADHD 179 (17.1)
 Depression 239 (22.9)
 PCOS 18 (1.7)
 Sleep apnea 9 (0.86)

Medications
 Antipsychotics 98 (9.4)
 Anxiolytics 77 (7.36)
 Antidepressants 278 (26.6)
 Psychostimulants 167 (16.0)
 Antihypertensives 55 (5.3)
 Antidiabetics 42 (4.0)

Prior primary healthcare utilization over 1 year 4 (6)

Prior specialist referral
 Gastroenterology 34 (3.25%)
 Pediatrics 231 (22.1%)
 Endocrinology 53 (5.07%)
 Weight clinic/dietician 2 (0.19%)

Reported as median (interquartile range); BMI, body mass index; ALT, alanine transaminase; ADHD, attention deficit hyperactivity disorder; PCOS, polycystic ovarian syndrome.